Using genetic variants that naturally lower lipoprotein(a) levels as proxies for future Lp(a)-targeting drugs, researchers analyzed pregnancy outcomes in 714,899 women across multiple studies. The Mendelian randomization approach found no strong evidence that substantial Lp(a) reduction increases risk of 20 adverse pregnancy outcomes, including gestational hypertension, preeclampsia, gestational diabetes, or miscarriage. Small protective associations emerged for gestational age and birth defects, while slightly elevated risks appeared for stillbirth and low Apgar scores, though confidence intervals were wide. This genetic evidence provides crucial safety data as pharmaceutical companies develop Lp(a)-lowering therapies for cardiovascular protection. Since elevated Lp(a) affects roughly 20% of the global population and increases heart disease risk by 50-100%, effective treatments could benefit millions. However, pregnancy safety has remained a key concern for regulatory approval. The findings suggest these emerging therapies likely won't require pregnancy restrictions, though modest effects on rare outcomes can't be ruled out. As a preprint awaiting peer review, these results require validation, but they offer reassuring preliminary evidence for an important class of cardiovascular drugs in development.